FDA approves much-debated Alzheimer's drug panned by experts U.S. government health officials on Monday approved the first new drug for Alzheimer's disease in nearly 20 years, disregarding warnings. Zeposia: new oral treatment for relapsing-remitting multiple sclerosisThird oral sphingosine 1-phosphate receptor modulator to be marketed for MS in Canada. Greater risk of bladder cancer in people with MS: study Ketogenic medium chain triglyceride drink improves cognition in mild cognitive impairment Already available in Europe, Nestlé aims to launch BrainXpert as a Natural Health Product in Canada in 2022. Managing sleep disturbances in Parkinson’s Disease The majority of people with PD experience nonmotor symptoms, such as insomnia, which are often under-recognized and poorly managed. Epidural anesthesia during labour may increase risk of autism spectrum disorders in children Study finds 37% increased risk of autism spectrum disorders, with risk increasing with longer duration of epidural anesthesia. Emgality (galcanezumab) now indicated to reduce cluster headache frequency CGRP binding antibody is first drug approved by Health Canada to help prevent episodic cluster headaches What is the best treatment for medication overuse headache? Study examines three treatment strategies for medication overuse headache Suspect COVID-19 in patients presenting with neurological symptoms Neurological manifestations may include impaired consciousness, stroke, ataxia, seizure, taste/smell impairment, vision impairment, nerve pain and skeletal muscle pain Watch for drug interactions with cannabinoids in marijuana Select alternate drugs that do not interact with marijuana when clinically feasible First Previous 28 29 30 31 32 Next Last
